References
- Weledji EP. Benefits and risks of splenectomy. Int J Surg 2014; 12:113–119.
- Kristinsson SY, Gridley G, Hoover RN, et al. Long-term risks after splenectomy among 8,149 cancer-free US veterans: a cohort study with up to 27 years follow-up. Haematologica 2014;99:392–398.
- Mellemkjøer L, Olsen JRH, Linet MS, et al. Cancer risk after splenectomy. Cancer 1995;75:577–583.
- Dietrich P, Henry-Amar M, Cosset J, et al. Second primary cancers in patients continuously disease-free from Hodgkin’s disease: a protective role for the spleen? Blood 1994;84:1209–1215.
- van Leeuwen FE, Klokman W, Hagenbeek A, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994;12:312–325.
- Hull CC, Galloway P, Gordon N, et al. Splenectomy and the induction of murine colon cancer. Arch Surg 1988;123:462.
- Sato N, Michaelides MC, Wallack MK. Effect of splenectomy on the growth of murine colon tumors. J Surg Oncol 1983;22:73–76.
- Dailey MO, Coleman CN, Fajardo LF. Splenic injury caused by therapeutic irradiation. Am J Surg Pathol 1981;5:325–332.
- Holroyde CP, Oski FA, Gardner FH. The pocked erythrocyte: red-cell surface alterations in reticuloendothelial immaturity of the neonate. N Engl J Med 1969;281:516–520.
- Bonadonna G, Viviani S, Bonfante V, et al. Survival in Hodgkin's disease patients—report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005;41:998–1006.
- Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096–4104.
- Delwail V, Jais JP, Colonna P, et al. Fifteen–year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high–dose irradiation. Br J Haematol 2002;118:189–194.
- van Leeuwen FE, Klokman WJ, van't Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487–497.
- Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36:252–259.
- Kooistra HAM, Kluin-Nelemans HC, van Imhoff GW, et al. Splenectomy and second malignancies in patients with Hodgkin lymphoma. Leuk Lymphoma 2015;56:242–243.